Pharmacopeia told it is not in compliance with Nasdaq listing

12 October 2008

Pharmacopeia, an innovator in the discovery and development of novel small molecule therapeutics, says it received a notice on September 30 from the Nasdaq Stock Market indicating that the company is not in compliance with the continued listing requirements of The Nasdaq Global Market under Nasdaq Marketplace Rule 4450(b)(1)(A). The firm received this notice because the market value of its listed securities was below $50.0 million for 10 consecutive trading days. The notice further states that the company is not in compliance with the alternative test under Nasdaq Marketplace Rule 4450(b)(1)(B), which requires total assets and total revenue of $50.0 million each for the most recently completed fiscal year or two of the last three most recently completed fiscal years. The notification has no immediate effect on the listing of the company's common stock on the Nasdaq.

Pharmacopeia may regain compliance with the minimum market value of listed securities standard if, at anytime prior to October 30,its market value is $50.0 million or more for a minimum of 10 consecutive business days (or such longer period of time as may be required by Nasdaq, at its discretion). If it has not demonstrated compliance by that date, the Nasdaq will provide the company with written notice that its securities will be de-listed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight